Helix BioPharma Corp. is facing a notable decline, with shares down 4.14% in the last trading session.
Helix BioPharma Corp. (HBP.TO) had a tough day on the TSX, closing at CA$1.39 after a 4.14% drop. This decline reflects ongoing market pressures and investor concerns about the company's financial health and future prospects.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$114.57M
52W high
$5.40
52W low
$0.98
1W change
+2.07%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 68.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+68.9% Upside
Current Price
C$1.48
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
48.7%
Annualized
90-Day Vol
65.6%
Annualized
Trend (90d)
-43.1%
Annualized drift
90d Mean
C$1.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.19 – C$1.66 |
| 60 trading days | C$1.34 | C$1.05 – C$1.69 |
| 90 trading days | C$1.27 | C$0.95 – C$1.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep a close eye on Helix BioPharma's financial strategies and market positioning, especially considering its recent performance and the need for additional financing.
4.14% Drop in Stock Price
Helix BioPharma's stock fell to CA$1.39, raising questions about its financial stability.
Bull case
If Helix BioPharma secures the necessary funding and advances its therapeutic programs, it could recover and offer long-term growth opportunities.
Bear case
Ongoing financial losses and a lack of immediate positive news could continue to weigh on investor sentiment, leading to further declines in stock price.
Advertisement
Market Reaction to Financial Performance
Helix BioPharma's recent financial results have not instilled confidence among investors. The company reported a net loss of $5,205,000 for the fiscal year ending July 31, 2025. While this is a slight improvement from the previous year, it still highlights ongoing challenges. As the market processes this information, the stock's decline reflects a cautious approach from investors.
Future Funding Needs
With the company focusing on securing financing for its next phase, the lack of immediate positive news has created uncertainty. Helix BioPharma has engaged in private placements to raise capital, but it remains to be seen how effective these measures will be. Investors should be prepared for potential volatility as the company navigates its financial landscape.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
